The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Open accessAbstract
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As an extension of MR, drug target MR has emerged as efficient way to estimate therapeutic potential by using genetic variants in genes encoding drug targets (referred to as cis variants) to mimic the actions of drugs.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, these observations are supported by data from a recent mendelian randomization study in which variants in PCSK9 and variants in HMGCR were associated with nearly identical lower risks of cardiovascular events per unit reduction in LDL cholesterol.29”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [29]
In the citing paper
“mendelian randomisation studies 8,[19][20][21] of genetic polymorphisms that mimic the effects of statins, ezetimibe, or PCSK9 inhibitors suggest that lifelong reductions in LDL cholesterol, irrespective of the mechanism, are associated with an increased risk of diabetes.”
In the citing paper
“Mendelian randomisation analyses 8,20,21 have shown that genetically determined loss of function of PCSK9 is associated with an increased risk of incident diabetes, but clinical trials of PCSK9 inhibitors have shown no such effect.9”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationMulti-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citation
Cited by
Sorted by citations
Items 401–500 of 747
The Link between miRNAs and PCKS9 in Atherosclerosis
Mačvanin, M., Gluvic, Z. M., Klisic, A. N., Manojlovic, M. S., Suri, J. S., Rizzo, M., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673262124231102042914 · Cited by 13
Kuniholm, M. H., Liang, H., Anastos, K., Gustafson, D., Kassaye, S., Nowicki, M. J., Sha, B. E., Pawlowski, E., Gange, S. J., Aouizerat, B. E., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001648 · Cited by 11
Ziegler, T., Bähr, A., Howe, A., Klett, K., Husada, W., Weber, C., Laugwitz, K., Kupatt, C., & Hinkel, R. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.004 · Cited by 11
Wang, S., Xiu, J., Liao, W., Liao, Y., & Bin, J. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-1321 · Cited by 11
Nishikido, T., & Ray, K. K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14851 · Cited by 11
Wu, J., Wang, Y., Kang, K., Wang, A., Xu, J., & Zhao, X. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000430 · Cited by 11
Phenotype Harmonization in the GLIDE2 Oral Health Genomics Consortium
Divaris, K., Haworth, S. J., Shaffer, J. R., Anttonen, V., Beck, J. D., Furuichi, Y., Holtfreter, B., Jönsson, D., Kocher, T., Levy, S. M., et al. (2022) · Journal of Dental Research · doi:10.1177/00220345221109775 · Cited by 11
Primary prevention of cardiovascular disease in women
Gray, M. P., Vogel, B., Mehran, R., Leopold, J. A., & Figtree, G. A. (2024) · Climacteric · doi:10.1080/13697137.2023.2282685 · Cited by 11
Geranylgeranyl isoprenoids and hepatic Rap1a regulate basal and statin-induced expression of PCSK9
Wang, Y., Tinsley, B., Spolitu, S., Zadroga, J. A., Agarwal, H., Sarecha, A. K., & Özcan, L. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100515 · Cited by 10
Lee, P. C., Jung, I., Thussu, S., Patel, V., Wagoner, R., Burks, K. H., Amrute, J., Elenbaas, J. S., Kang, C. J., Young, E. P., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110104 · Cited by 11
Jamadade, P., Nupur, N., Maharana, K. C., & Singh, S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01228-0 · Cited by 11
Rosoff, D. B., Wagner, J., Jung, J., Pacher, P., Christodoulides, C., Davey Smith, G., Ray, D., & Lohoff, F. W. (2025) · Diabetes · doi:10.2337/db24-0451 · Cited by 10
Fujino, M., Giovanni, G. D., Butters, J., Kataoka, Y., Hucko, T., Nelson, A. J., Nissen, S. E., Psaltis, P. J., & Nicholls, S. J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119145 · Cited by 10
Lipids and Lipoproteins in Risk Prediction
Hadjiphilippou, S., & Ray, K. K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.002 · Cited by 10
Association of low-density lipoprotein-cholesterol with all-cause and cause-specific mortality
Wu, M., Liao, S., Si, J., Guo, X., Kang, L., Xu, B., & Liu, Y. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102784 · Cited by 10
Luo, S., Lam, H. S., Chan, Y. H., Tang, C. S.-M., He, B., Kwok, M. K., Leung, G. M., Schooling, C. M., & Yeung, S. L. A. (2023) · BMC Medicine · doi:10.1186/s12916-023-03115-y · Cited by 10
Association between serum PCSK9 and coronary heart disease in patients with type 2 diabetes mellitus
Huang, J., Gu, J.-X., Wang, K., Zhang, A., Hong, T.-T., Li, S.-S., Yao, X., Yang, M. J., Yin, Y., Zhang, N., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01238-z · Cited by 11
Lohoff, F. W. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy087 · Cited by 10
Kattih, B., Elling, L. S., Weiß, C., Bea, M., Zwadlo, C., Bavendiek, U., Bauersachs, J. K., & Heineke, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-46640-8 · Cited by 10
The Use of Genomics to Drive Kidney Disease Drug Discovery and Development
Reilly, D. F., & Breyer, M. D. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11070919 · Cited by 10
Lyons, P., Peters, J. E., Alberici, F., Liley, J., Coulson, R., Astle, W. J., Baldini, C., Bonatti, F., Cid, M. C., Elding, H., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/491837 · Cited by 10
Bandaru, M. K., Emmanouilidou, A., Ranefall, P., von der Heyde, B., Mazzaferro, E., Klingström, T., Masiero, M. M., Dethlefsen, O., Ledin, J., Larsson, A. O., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/502674 · Cited by 10
Genetic drug target validation using Mendelian randomizationPreprint
Schmidt, A. F., Finan, C., Gordillo‐Marañón, M., Asselbergs, F. W., Freitag, D. F., Patel, R. S., Tyl, B., Chopade, S., Faraway, R., Zwierzyna, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/781039 · Cited by 10
Masson, W. M., Lobo, M., Barbagelata, L., & Nogueira, J. P. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02205-w · Cited by 9
Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Pham, K., Mulugeta, A., Lumsden, A. L., & Hyppönen, E. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15793 · Cited by 9
Brumpton, B. M., Fritsche, L. G., Zheng, J., Nielsen, J. B., Mannila, M. N., Surakka, I. L., Rasheed, H., Vie, G. Å., Graham, S. E., Gabrielsen, M. E., et al. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002335 · Cited by 9
Polygenic modelling of treatment effect heterogeneity
Xu, Z. M., & Burgess, S. (2020) · Genetic Epidemiology · doi:10.1002/gepi.22347 · Cited by 9
Ghouse, J., Ahlberg, G., Skov, A. G., Bundgaard, H., & OLESEN, M. S. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025361 · Cited by 9
Scientific Contributions of Population-Based Studies to Cardiovascular Epidemiology in the GWAS Era
Lieb, W., & Vasan, R. S. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00057 · Cited by 8
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Nicholls, S. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1103-2 · Cited by 10
PCSK9 in diabetes: sweet, bitter or sour?
Paneni, F., & Costantino, S. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy432 · Cited by 9
Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book
Santos, R. D., & Rocha, V. Z. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac656 · Cited by 9
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Self-citationLu, F., Li, E., & Yang, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19371 · Cited by 8
Zhao, S., Xie, Y., Xu, D., Zheng, C., Chen, J., Zhao, N., Ji, Y., Wang, Q., Liu, Y., & Cheng, C. (2024) · Environmental Toxicology · doi:10.1002/tox.24210 · Cited by 8
Mendelian randomization study of whole blood viscosity and cardiovascular diseases
Bhak, Y., & Tenesa, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0294095 · Cited by 10
Metabolomics Profiling of Stages of Coronary Artery Disease Progression
Anlar, G. G., Anwardeen, N. R., Ashmar, S. A., Pedersen, S., Elrayess, M. A., & Zeidan, A. (2024) · Metabolites · doi:10.3390/metabo14060292 · Cited by 9
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins
Capuozzo, M., Ottaiano, A., Cinque, C., Farace, S., & Ferrara, F. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2024.12.002 · Cited by 8
Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
Salah, A. N., Hashem, A. H., Zaki, M. B., Abulsoud, A. I., Atta, A. M., Elkalla, W. S., Moustafa, H. A. M., El‐Dakroury, W. A., El-Tokhy, F. S., ElBoghdady, J. A., et al. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70163 · Cited by 9
Revaiah, P. C., Serruys, P. W. J. C., Onuma, Y., Andreini, D., Budoff, M. J., Sharif, F., Chernofsky, A., Vikarunnessa, S., Wiethoff, A. J., Yates, D. P., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.08.001 · Cited by 10
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
Li, F., Mei, Y., Wu, Q., & Wu, X. (2024) · Cardiology · doi:10.1159/000538551 · Cited by 8
Velidakis, N., Stachteas, P., Gkougkoudi, E., Papadopoulos, C. E., & Kadoglou, N. P. E. (2024) · Pharmaceuticals · doi:10.3390/ph17050568 · Cited by 8
Effects of Evolocumab on Cardiovascular Events
Mikhail, N. E. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170918165713 · Cited by 9
Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders
Trajanoska, K., & Rivadeneira, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.556610 · Cited by 8
Li, Y., Xiao, W., Huang, N., Zhuang, Z., Zhang, L., Wang, W., Song, Z., Zhao, Y., Xue, D. Q., Xu, M., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.04.007 · Cited by 7
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Béliard, S., Mourre, F., & Valéro, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06100-z · Cited by 8
Evolocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1365134 · Cited by 8
Hypolipidemic Drugs and Diabetes Mellitus—Mechanisms and Data From Genetic Trials
Filippatos, T. D., Panagiotopoulou, T., Tzavella, E., & Elisaf, M. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418757011 · Cited by 8
Xue, J., Yu, S., Jincai, W., Li, C., Yang, M., & Yongli, S. (2020) · Planta Medica · doi:10.1055/a-1147-9196 · Cited by 8
Zhang, Y., Li, Y., Liu, Y., Willett, W. C., Manson, J. E., Stampfer, M. J., Hu, F. B., Giovannucci, E. L., & Wang, D. D. (2025) · Diabetologia · doi:10.1007/s00125-025-06441-3 · Cited by 7
Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors
Balakrishna, A. M., Kaushik, S., Tandalam, S., Monther, N., Ponamgi, S., Alla, V. M., & Patil, S. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134562 · Cited by 8
Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future
Sabatine, M. S., & Laufs, U. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag148 · Cited by 7
Self-citationVariation in VEGFA and risk of cardiovascular disease in the UK Biobank
Chen, H., Lv, X., Yang, J., Chen, Z., Qiao, W., Zhou, T. Y., & Zhang, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1240288 · Cited by 7
Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation
Zeng, W., & Tomlinson, B. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2424411 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia
Khoury, É., Brisson, D., & Gaudet, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1704728 · Cited by 6
Kajingulu, F., Lepira, F. B., Nkodila, A. N., Makulo, J.-R. R., Mokoli, V. M., Ekulu, P. M., Bukabau, J. B., Nlandu, Y. M., Longo, A. L., Nseka, N. M., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02748-0 · Cited by 8
Li, X., Li, Y., Zhao, W., Yu, L., Hu, X., Zhao, Y., Guo, Q., Wang, X., & Wu, X. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200146 · Cited by 7
Zhao, X., Tang, X., Xu, J., Liu, R., Huang, K., Li, J., Li, Y., Jiang, L., Xu, L., Zhang, Y., et al. (2022) · The Journal of Gene Medicine · doi:10.1002/jgm.3445 · Cited by 7
Vörös, S., Bansal, A. T., Barnes, M. R., Narula, J., Maurovich‐Horvat, P., Vazquez, G., Marvasty, I. B., Brown, B. O., Voros, I. D., Harris, W. S., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.960419 · Cited by 7
Self-citationWhat the diabetes data in the FOURIER trial fail to show
van Bruggen, F. H., & Luijendijk, H. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13576 · Cited by 7
Müller‐Wieland, D., Rader, D. J., Moriarty, P. M., Bergeron, J., Langslet, G., Ray, K. K., Manvelian, G. Z., Thompson, D. E., Bujas‐Bobanovic, M., & Roth, E. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02703 · Cited by 7
Evolving concepts on the management of dyslipidaemia
Descamps, O. S., Verhaegen, A. A., Demeure, F., Langlois, M. R., Rietzschel, E. R., Mertens, A. C., SUTTER, J. D., Wallemacq, C. M., Lancellotti, P., & Backer, G. D. (2019) · Acta Clinica Belgica · doi:10.1080/17843286.2019.1702823 · Cited by 7
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
Self-citationLi, B., Chen, Y., Zhang, Y., Qian, M., Shan, Q., Qian, J., & Guo, J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468855 · Cited by 6
Guo, J., Liu, R., Sheng, F., Wu, Q., Xu, R., He, H., Zhang, G., Huang, J., Zhang, Z., & Zhang, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1294297 · Cited by 6
Liu, S., Wan, J., Wang, D., Yang, Y., Fang, J., Luo, T., Liang, D., Hu, J., Hou, J., & Wang, P. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.04.007 · Cited by 6
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?
Nicholls, S. J., Tan, S., Butters, J., & Nelson, A. J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2409324 · Cited by 6
Cardiovascular risk management beyond statins: review of new therapies available in Italy
Capuozzo, M., Ottaiano, A., Cinque, C., Farace, S., & Ferrara, F. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00660-0 · Cited by 7
A safety evaluation of evolocumab
Roth, E. M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1389892 · Cited by 7
Wang, J., Han, P., Gao, M., Xiao, J.-Y., Li, X., Zhang, N., Ma, J., Cui, Z., Yao, T., Chen, Y., et al. (2021) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2021.05.002 · Cited by 6
HMG-Coenzyme A Reductase as a Drug Target for the Prevention of Ankylosing Spondylitis
Zhong, Z., Feng, X., Su, G., Du, L., Liao, W., Liu, S., Li, F., Zuo, X., & Yang, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.731072 · Cited by 6
Basal metabolic rate and risk of multiple sclerosis: a Mendelian randomization study
Liu, C., Lu, Y., Chen, J., Qiu, W., Zhan, Y., & Liu, Z. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00973-y · Cited by 6
Giuliani, A., Montesanto, A., Matacchione, G., Graciotti, L., Ramini, D., Protic, O., Galeazzi, R., Antonicelli, R., Tortato, E., Bonfigli, A. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105617 · Cited by 6
A translational framework of genoproteomic studies for cardiovascular drug discovery
Yang, Z., Zhao, J. V., Qi, Y., Deng, X., Ji, Z., & Liu, J. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00015-9 · Cited by 6
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Sugiyama, K., & Saisho, Y. (2018) · Diseases · doi:10.3390/diseases6020044 · Cited by 6
Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease
Buckley, L. F., Carbone, S., Aldemerdash, A. M., Fatani, N., & Fanikos, J. R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.08.019 · Cited by 6
Targeting LDL cholesterol: Early treatment is key to population health
Stock, J. K. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.013 · Cited by 6
Han, E., Cho, N. H., Moon, S., & Cho, H. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.480 · Cited by 6
Protective lipid-lowering variants in healthy older individuals without coronary heart disease
Lacaze, P. A., Riaz, M., Sebra, R., Hooper, A. J., Pang, J., Tiller, J. M., Polekhina, G., Tonkin, A. M., Reid, C. M., Zoungas, S., et al. (2021) · Open Heart · doi:10.1136/openhrt-2021-001710 · Cited by 7
Quiroga, B., Ramos, P. M., & Chiva, V. Á. (2020) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2020.11.004 · Cited by 6
PCSK9 inhibitors: what we know, what we should have understood, and what is to come
Sabatine, M. S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz514 · Cited by 7
Self-citationStatistical Methods for cis-Mendelian RandomizationPreprint
Gkatzionis, A., Burgess, S., & Newcombe, P. J. (2021) · arXiv (Cornell University) · Cited by 6
Yang, L., Xu, M., Gao, X., Liu, J., Zhang, D., Zhang, Z., Ye, Z., Wen, J., & Liu, P. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508292 · Cited by 6
Liang, H., Tang, C., Sun, Y., Wang, M., Tong, T., Gao, Q., Xie, H., & Tan, T. (2024) · Discover Oncology · doi:10.1007/s12672-024-01684-9 · Cited by 5
Ghouse, J., Ahlberg, G., Bundgaard, H., & OLESEN, M. S. (2021) · Diabetes Care · doi:10.2337/dc21-0955 · Cited by 5
Alsehli, A. M., Rukh, G., Clemensson, L. E., Ciuculete, D. M., Tan, X. W., Al-Sabri, M. H., Williams, M. J., Benedict, C., & Schiöth, H. B. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5039 · Cited by 5
How clinically relevant is statin-induced diabetes?
Gerstein, H. C., & Pigeyre, M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00059-7 · Cited by 5
Bovijn, J., Krebs, K., Chen, C., Boxall, R., Censin, J. C., Ferreira, T. C., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf4530 · Cited by 5
Li, S., & Schooling, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-07344-8 · Cited by 8
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
Parham, J. S., & Goldberg, A. C. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01036-4 · Cited by 5
Chen, W., Wang, Y., Meng, X., Pan, Y., Wang, M., Li, H., Wang, Y., & Wang, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-870 · Cited by 5
Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization
Jiang, Z., Gu, X., Su, W., Duan, Q., Yin, K., Ren, Y., Wang, Y., Cao, B., & Chen, Y. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04007-9 · Cited by 5
Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects
Nuglozeh, E., Fazaludeen, M. F., Hasona, N. A., Malm, T., Mayor, L. B., Al-Hazmi, A., & Ashankyty, I. (2018) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-018-0763-9 · Cited by 5
Santos, R. D. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000460 · Cited by 5
Kar, S., Brenner, H., Giles, G. G., Huo, D., Milne, R. L., Rennert, G., Simard, J., Zheng, W., Burgess, S., & Pharoah, P. D. P. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz047 · Cited by 5
Identifying and Validating New Drug Targets for Stroke and Beyond
Plump, A. S., & Smith, G. D. (2019) · Circulation · doi:10.1161/circulationaha.119.042005 · Cited by 4
Metadata
- Authors
- Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., & Sabatine, M. S.
- Affiliations
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12
- Volume
- 375
- Issue
- 22
- Pages
- 2144-2153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2557654447
- Cited by
- 743
- References
- 39
- Citations by year
- 2026: 38 · 2025: 55 · 2024: 77 · 2023: 64 · 2022: 74 · 2021: 76 · 2020: 75 · 2019: 86 · 2018: 97 · 2017: 92 · 2016: 8
- FWCI
- 104.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PCSK9, HMGCR, LDL cholesterol, cardiovascular disease, diabetes mellitus, genetic variants, PCSK9 inhibitors, statins, genetic score, impaired fasting glucose, additive genetic effects, cardiovascular risk prediction, LDL-C lowering therapy, HMG-CoA reductase inhibition, cardiovascular events, diabetes risk
- MeSH terms
- Proprotein Convertase 9, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Random Allocation, Risk, Genetic Variation, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
